公开(公告)号：US20220241412A1

公开(公告)日：2022-08-04

申请号：US17613557

申请日：2020-05-20

Applicant: Pfizer Inc. ,  MERCK PATENT GMBH

Inventor： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC: A61K39/395 ,  A61K31/519 ,  A61P35/00

Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 or a CDK2/4/6 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an OX40 agonist and/or a 4-1BB agonist to a subject in need thereof.

公开(公告)号：US20230053328A9

公开(公告)日：2023-02-16

申请号：US17613304

申请日：2020-05-21

Applicant: Pfizer Inc.

Inventor： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC: C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  A61P35/00

Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.

公开(公告)号：US20230158034A1

公开(公告)日：2023-05-25

申请号：US17995619

申请日：2021-04-07

Applicant: Pfizer Inc. ,  THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Mansi Arora ,  Stephen George Dann ,  Nichol Lee Goodman Miller ,  Sabrina Spencer ,  Todd Lee VanArsdale

IPC: A61K31/519 ,  A61K31/506 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/506 ,  A61P35/00

Abstract: The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.

公开(公告)号：US20220235141A1

公开(公告)日：2022-07-28

申请号：US17613304

申请日：2020-05-21

Applicant: Pfizer Inc.

Inventor： Stephen George Dann ,  Cecilia Marianne Oderup ,  Shahram Salek-Ardakani

IPC: C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  A61P35/00

Abstract: This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.